Pediatric Cancer Studies Triggered by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) Aim at Labels, Not at Improved Treatment

被引：0
|
作者：
Rose, K. [1 ]
机构：
[1] Klausrose Consulting, Med Sci, CH-4125 Riehen, Switzerland
来源：
PEDIATRIC BLOOD & CANCER | 2019年 / 66卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
V409 SIOP1
引用
收藏
页码：S361 / S362
页数：2
相关论文
共 50 条
  • [21] Magnitude of clinical benefit in trials supporting US Food and Drug Administration (FDA) accelerated approval (AA) and European Medicines Agency (EMA) conditional marketing authorisation (CMA) and subsequent trials supporting conversion to full approval
    Borrell Puy, M.
    Molto Valiente, C.
    Vokinger, K.
    Hwang, T.
    Ocana Fernandez, A.
    Templeton, A. J.
    Seruga, B.
    Gich Saladich, I.
    Barnadas, A.
    Amir, E.
    Tibau, A.
    ANNALS OF ONCOLOGY, 2018, 29
  • [22] Comparison of COVID-19 Vaccine Approvals at the US Food and Drug Administration, European Medicines Agency, and Health Canada
    Lythgoe, Mark P.
    Middleton, Paul
    JAMA NETWORK OPEN, 2021, 4 (06)
  • [23] Descriptive Analysis of Good Clinical Practice Inspection Findings from US Food and Drug Administration and European Medicines Agency
    Sellers, Jenn W.
    Mihaescu, Camelia M.
    Ayalew, Kassa
    Kronstein, Phillip D.
    Yu, Bei
    Ning, Yang-Min
    Rodriguez, Miguel
    Williams, LaKisha
    Khin, Ni A.
    THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2022, 56 (05) : 753 - 764
  • [24] CHARACTERISTICS OF CELL AND GENE THERAPIES AUTHORIZED BY THE FOOD AND DRUG ADMINISTRATION AND THE EUROPEAN MEDICINES AGENCY
    Kamerikar, V
    Dheer, P.
    Bermudez, B. L.
    Shukla, V
    Rodriguez-Monguio, R.
    Fleming, M.
    Seoane-Vazquez, E.
    VALUE IN HEALTH, 2024, 27 (06) : S256 - S256
  • [25] An Analysis of Regulatory Timing and Outcomes for New Drug Applications Submitted to Swissmedic: Comparison With the US Food and Drug Administration and the European Medicines Agency
    Dorr, Petra
    Wadworth, Alison
    Wang, Tina
    McAuslane, Neil
    Liberti, Lawrence
    THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2016, 50 (06) : 734 - 742
  • [26] An Analysis of Regulatory Timing and Outcomes for New Drug Applications Submitted to Swissmedic: Comparison With the US Food and Drug Administration and the European Medicines Agency
    Petra Dörr
    Alison Wadworth
    Tina Wang
    Neil McAuslane
    Lawrence Liberti
    Therapeutic Innovation & Regulatory Science, 2016, 50 : 734 - 742
  • [27] Overall survival after PARP maintenance treatment in platinum-sensitive relapsed ovarian cancer: opposing views of the US Food and Drug Administration and European Medicines Agency
    Monk, Bradley J.
    Coleman, Robert L.
    Mirza, Mansoor Raza
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 (06) : 1008 - 1009
  • [28] Evaluation of designs for renal drug studies based on the European Medicines Agency and Food and Drug Administration guidelines for drugs that are predominantly secreted
    Pradhan, Sudeep
    Wright, Daniel F. B.
    Duffull, Stephen B.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2021, 87 (03) : 1401 - 1410
  • [29] Evaluation of Oncology Drugs at the European Medicines Agency and US Food and Drug Administration: When Differences Have an Impact on Clinical Practice
    Trotta, Francesco
    Leufkens, Hubert G. M.
    Schellens, Jan H. M.
    Laing, Richard
    Tafuri, Giovanni
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (16) : 2266 - 2272
  • [30] Comparison between European Medicines Agency and US Food and Drug Administration in Granting Accelerated Marketing Authorizations for Covid-19 Medicines and their Utilized Regulations
    Ghadanian, Marina
    Schafheutle, Ellen
    THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2024, 58 (01) : 79 - 113
12345